LILRA6 CAR-T therapy for relapsed or refractory acute myeloid leukemia.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, open-label, single-arm Phase I study delivers LILRA6-directed CAR-T cells by intravenous infusion to adults with relapsed or refractory AML that express LILRA6. The dose-escalation phase uses a conventional 3+3 design to identify a safe and tolerable dose, with at least 28 days of close safety monitoring and up to two years of follow-up for each patient. After a recommended dose is selected based on safety, persistence, and preliminary efficacy, an approximately 30-patient dose-expansion cohort will further evaluate safety and anti-leukemia activity. All treated patients will continue long-term follow-up for up to two years post-infusion.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily participate in this study and sign the informed consent form.
2. Age range: 18 - 75 years old. Gender is not restricted.
3. Refractory/Recurrent AML: Meeting any one of the following criteria for refractory or recurrent cases is sufficient. 1) Refractory: (1) In the case of a newly diagnosed patient, treatment with the standard regimen for two courses fails to achieve complete remission (CR); (2) Recurrence within 12 months after consolidation and intensification therapy following CR; (3) Recurrence after 12 months with no response to salvage chemotherapy; (4) ≥ 2 recurrences; (5) Persistent extramedullary leukemia; 2) Recurrence: (1) Leukemia cells reappear in the peripheral blood after complete remission (CR) of AML; (2) The percentage of blasts in the bone marrow is ≥ 5% (excluding other reasons such as bone marrow regeneration after consolidation chemotherapy); (3) Infiltration of leukemia cells in sites other than the bone marrow (excluding the central nervous system).
4. Expected survival period ≥ 12 weeks.
5. The positive rate of LILRA6 expression in bone marrow/tumor cells is ≥ 20%
6. ECOG score ranging from 0 to 2 points.
7. Sufficient organ function reserve: Alanine aminotransferase and Aspartate aminotransferase ≤ 2.5× UNL (upper limit of normal value); Creatinine clearance rate (Cockcroft-Gault method) ≥ 45 mL/min; Serum total bilirubin ≤ 1.5× UNL; Ejection fraction of the heart (EF) ≥ 45%; In an indoor natural air environment, baseline oxygen saturation \> 92%; Blood routine: All of the following criteria are met: Absolute number of neutrophils ≥ 0.5×10\^9 /L, Platelet count ≥ 30×10\^9 /L, Hemoglobin ≥ 7.0 g/dl.
8. Allow those who have previously undergone a single autologous hematopoietic stem cell transplantationAllowing previous recipients of a single autologous hematopoietic stem cell transplantation.
9. Pregnancy tests for the female subjects of childbearing age must be negative, and they must also agree to take effective contraceptive measures during the trial.
10. There are no uncontrollable infectious activities (including lung infections).
11. Distance from the last anti-tumor treatment: Systemic chemotherapy / systemic radiotherapy / immunotherapy ≥ 3 weeks, targeted drug elution period ≥ 2 weeks.
12. No active infection of the novel coronavirus or influenza.

Exclusion Criteria:

1. Those who have a severe history of allergic reaction to any component of the cell preparation or the pre-treatment chemotherapy drugs.
2. Those with a history of other active malignant tumors.
3. There are active infections that require treatment (excluding simple urinary tract infections and bacterial pharyngitis); the use of prophylactic antibiotics, antiviral drugs, and antifungal drugs is permitted.
4. Active hepatitis B (with HBsAg positive and HBV-DNA ≥ 10³ copies/mL), hepatitis C infection, syphilis, or other acquired/innate immune deficiency disorders (including HIV infection).
5. According to the New York Heart Association (NYHA) classification of cardiac function, those with cardiac function at grade III or IV.
6. Previous anti-tumor treatment-related toxic reactions have not yet recovered to a grade ≤ 1 (according to CTCAE 5.0), except for fatigue, anorexia and hair loss.
7. Those with a history of epilepsy or other central nervous system diseases that may affect the research assessment.

8: Those who have received any other targeted LILRA6 drug treatment before. 9.Breastfeeding women who do not wish to stop breastfeeding. 10.The researchers believe that there may be any other circumstances that could increase the risks for the subjects or interfere with the test results.

Where it's running

• The Second Affiliated Hospital,School of Medicine,Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Wenbin Qian, Professor
• Email: qianwb@zju.edu.cn
• Phone: 13605801032

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CD83-targeted CAR T cell therapy for adults with relapsed or refractory acute myeloid leukemia

  This Phase 1 trial tests a personalized CD83-targeted CAR T-cell infusion to try to eliminate leukemia cells in adults whose AML has relapsed or not responded to prior treatment.

  Recruiting Phase 1 Roswell Park Cancer Institute · Buffalo, New York · NCT06871410

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Total marrow and lymphoid irradiation with fludarabine and melphalan for older adults with refractory/relapsed AML or high-risk MDS undergoing donor stem cell transplant

  This phase 2 trial tests a targeted radiation conditioning (TMLI) with fludarabine and melphalan before a matched donor stem cell transplant in people aged 50 or older with difficult-to-treat AML or high-risk MDS.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07582172

• MiRisten to treat relapsed or refractory acute myeloid leukemia

  This phase 1 trial tests whether intravenous miRisten, a miR-126 inhibitor, is safe and tolerable and may help adults with relapsed or refractory acute myeloid leukemia.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07025564

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

• Cedazuridine/decitabine with filgrastim dose escalation after stem cell transplant for children with high-risk AML

  This phase 1 trial will test whether giving the oral combination cedazuridine/decitabine (ASTX727) together with filgrastim is safe and find the highest tolerable dose for children with high-risk acute myeloid leukemia after allogeneic stem cell transplant.

  Recruiting at 14 sites Phase 1 National Cancer Institute (NCI) · Birmingham, Alabama and 14 other locations · NCT07012044

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.